$VXRT News

Vaxart Appoints Retired Vice Admiral Raquel C. Bono, M.D., to Board of Directors

Vaxart Announces Publication of Preclinical Study Demonstrating 100% Protection Against a Lethal Dose of H5N1 Avian Flu in a Ferret Challenge Model

Vaxart Announces Publication Of Preclinical Study Results Evaluating Its Oral Mucosal Vaccine Platform Against Highly Pathogenic Avian Influenza H5N1; Candidate VXA-H5-02 Induced Robust Cross-Neutralizing Antibodies

Vaxart, Inc. (VXRT) Presents at H.C. Wainwright 28th Annual Global Investment Conference - Slideshow

Vaxart Highlights Oral Vaccine Platform, COVID Trial Progress at H.C. Wainwright Conference

Vaxart to Present at the H.C. Wainwright 28th Annual Global Investment Conference

Vaxart, Inc. (VXRT) Q2 2026 Stockholder Fireside Chat Call Transcript

Vaxart Expands Intellectual Property Portfolio with European Patent Protecting Proprietary Norovirus Vaccine Technology

Vaxart Inc (VXRT) (Q2 2026) Earnings Call Highlights: Oral COVID Vaccine Shows Promise, Cash ...

Vaxart Q2 Earnings Call Highlights

Vaxart, Inc. (VXRT) Q2 2026 Earnings Call Transcript

Vaxart, Inc. Q2 2026 Earnings Call Summary

Vaxart Provides Business Update and Reports Second Quarter 2026 Financial Results

Vaxart to Host Stockholder Fireside Chat on August 7 at 4:30 p.m. ET

Vaxart to Participate in BTIG Biotechnology Conference 2026

Vaxart Investors Reject Say-on-Pay as CEO Rules Out Reverse Split for Now

Vaxart Announces Results of Annual Meeting of Stockholders

Vaxart Reports Topline 12-Month Safety Data From the 400-Participant Sentinel Safety Cohort of the Phase 2b Clinical Trial of Its Oral Pill COVID-19 Vaccine

Vaxart Enters Cooperation Agreement with Stockholder Group and Announces Board and Corporate Governance Enhancements

Vaxart Publishes Presentation Urging Shareholders to Vote “FOR” ALL Six of the Company’s Highly Qualified Director Nominees on the WHITE Proxy Card TODAY